{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:49:02Z","timestamp":1790740142127,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-IA-COH-2012\/3731"],"award-info":[{"award-number":["ANR-IA-COH-2012\/3731"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Programme Hospitalier de Recherche Clinique"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lilly France"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Sharp and Dohme-Chibret"},{"name":"Sanofi-Genzyme"},{"name":"Vifor Fresenius"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French National Institutes of Health and Medical Research Transfert"},{"name":"French National Agency for Medicines and Health Products Safety"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Little is known about the burden of adverse drug reactions in CKD. We estimated the incidence of overall and serious adverse drug reactions and assessed the probability of causation, preventability, and factors associated with adverse drug reactions in patients seen by nephrologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      The Chronic Kidney Disease-Renal Epidemiology and Information Network cohort included 3033 outpatients (65% men) with CKD and eGFR&lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , with follow-up for 2 years. Adverse drug reactions were identified from hospitalization reports, medical records, and participant interviews and finally assessed for causality, preventability, and immediate therapeutic management by experts in pharmacology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median (interquartile range) age was 69 (60\u201376) years old; 55% had eGFR\u226530 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , and 45% had eGFR&lt;30 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . Participants were prescribed a median (range) of eight (five to ten) drugs. Over 2 years, 536 patients had 751 adverse drug reactions, 150 (in 125 participants) classified as serious, for rates of 14.4 (95% confidence interval, 12.6 to 16.5) and 2.7 (95% confidence interval, 1.7 to 4.3) per 100 person-years, respectively. Among the serious adverse drug reactions, 32% were considered preventable or potentially preventable; 16 caused death, directly or indirectly. Renin-angiotensin system inhibitors (15%), antithrombotic agents (14%), and diuretics (10%) were the drugs to which the most adverse drug reactions were imputed, but antithrombotic agents caused 34% of serious adverse drug reactions. The drug was discontinued in 71% of cases, at least temporarily. Adjusted hazard ratios for serious adverse drug reaction were significantly higher in patients with eGFR&lt;30 versus \u226530 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (1.8; 95% confidence interval, 1.3 to 2.6), in those prescribed more than ten versus less than five medications (2.4; 95% confidence interval, 1.1 to 5.2), or in those with poor versus good adherence (1.6; 95% confidence interval, 1.4 to 2.4).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adverse drug reactions are common and sometimes serious in patients with CKD. Many serious adverse drug reactions may be preventable. Some specific pharmacologic classes, particularly antithrombotic agents, are at risk of serious adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number<\/jats:title>\n                    <jats:p>Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN), NCT03381950<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.01030120","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T16:49:36Z","timestamp":1593622176000},"page":"1090-1102","source":"Crossref","is-referenced-by-count":87,"title":["Adverse Drug Reactions in Patients with CKD"],"prefix":"10.2215","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03381950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03381950","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-5567","authenticated-orcid":false,"given":"Sol\u00e8ne M.","family":"Laville","sequence":"first","affiliation":[{"name":"Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, National Institute of Health and Medical Research, Center for research in Epidemiology and Population Health (CESP), Clinical Epidemiology Team, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Moragny","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Metzger","sequence":"additional","affiliation":[{"name":"Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, National Institute of Health and Medical Research, Center for research in Epidemiology and Population Health (CESP), Clinical Epidemiology Team, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacquelinet","sequence":"additional","affiliation":[{"name":"Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, National Institute of Health and Medical Research, Center for research in Epidemiology and Population Health (CESP), Clinical Epidemiology Team, Villejuif, France"},{"name":"Renal Epidemiology and Information Network Registry, Biomedicine Agency, Saint Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-573X","authenticated-orcid":false,"given":"Christian","family":"Combe","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantation Dialysis, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"Inserm Unit 1026, University of Bordeaux Segalen, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-7199","authenticated-orcid":false,"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[{"name":"Nephrology Department, Centre Hospitalier Lyon Sud, Universit\u00e9 de Lyon, Carmen, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Laville","sequence":"additional","affiliation":[{"name":"Nephrology Department, Centre Hospitalier Lyon Sud, Universit\u00e9 de Lyon, Carmen, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Frimat","sequence":"additional","affiliation":[{"name":"Nephrology Department, Centre Hospitalier R\u00e9gional Universitaire de Nancy, Vandoeuvre-l\u00e8s-Nancy, France"},{"name":"Lorraine University, APEMAC, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Stengel","sequence":"additional","affiliation":[{"name":"Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, National Institute of Health and Medical Research, Center for research in Epidemiology and Population Health (CESP), Clinical Epidemiology Team, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[{"name":"Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, National Institute of Health and Medical Research, Center for research in Epidemiology and Population Health (CESP), Clinical Epidemiology Team, Villejuif, France"},{"name":"Division of Nephrology, Ambroise Par\u00e9 University Hospital, Assistance publique \u2013 H\u00f4pitaux de Paris, Boulogne-Billancourt\/Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"},{"name":"MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/bmj.320.7241.1036","article-title":"Admissions to hospital caused by adverse drug reactions: Cross sectional incidence study. French Pharmacovigilance Centres","volume":"320","author":"Pouyanne","year":"2000","journal-title":"BMJ"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1345\/aph.1P627","article-title":"Prevalence of adverse drug events in ambulatory care: A systematic review","volume":"45","author":"Tach\u00e9","year":"2011","journal-title":"Ann Pharmacother"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/fcp.12088","article-title":"Incidence of hospital admissions due to adverse drug reactions in France: The EMIR study","volume":"29","author":"B\u00e9nard-Laribi\u00e8re","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/bcp.13081","article-title":"Prevalence and characteristics of adverse drug reactions at admission to hospital: A prospective observational study","volume":"82","author":"Chan","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2007.06.030","article-title":"Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in Greece","volume":"19","author":"Alexopoulou","year":"2008","journal-title":"Eur J Intern Med"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1046\/j.1532-5415.2002.50607.x","article-title":"Adverse drug reactions as cause of hospital admissions: Results from the Italian group of Pharmacoepidemiology in the elderly (GIFA)","volume":"50","author":"Onder","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archinte.165.7.790","article-title":"Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients","volume":"165","author":"Corsonello","year":"2005","journal-title":"Arch Intern Med"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40360-018-0243-0","article-title":"Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: A retrospective 3 year study","volume":"19","author":"Danial","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: A review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2000.00132.x","article-title":"Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine","volume":"49","author":"Fattinger","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: A case - noncase study of a pharmacovigilance database","volume":"83","author":"Pierson-Marchandise","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.47102\/annals-acadmedsg.V38N12p1095","article-title":"Drug use and dosing in chronic kidney disease","volume":"38","author":"Hassan","year":"2009","journal-title":"Ann Acad Med Singapore"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/sdi.12374","article-title":"A synopsis of clinical pharmacokinetic alterations in advanced CKD","volume":"28","author":"Nolin","year":"2015","journal-title":"Semin Dial"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: Results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1681\/ASN.2013090921","article-title":"Patient-reported and actionable safety events in CKD","volume":"25","author":"Ginsberg","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03030317","article-title":"Randomized clinical trial of sevelamer Carbonate on serum Klotho and fibroblast growth factor 23 in CKD","volume":"12","author":"Liabeuf","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"e95991","DOI":"10.1371\/journal.pone.0095991","article-title":"Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease","volume":"9","author":"Sharif-Askari","year":"2014","journal-title":"PLoS One"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jch.13563","article-title":"Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care","volume":"21","author":"Pecoits-Filho","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ndt\/gfy058","article-title":"Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study","volume":"34","author":"Stengel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B26-20230813","first-page":"839","article-title":"[Evaluation of patient compliance among hypertensive patients treated by specialists]","volume":"94","author":"Girerd","year":"2001","journal-title":"Arch Mal Coeur Vaiss"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ndt\/gfi198","article-title":"The renal epidemiology and information network (REIN): A new registry for end-stage renal disease in France","volume":"21","author":"Couchoud","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B31-20230813","first-page":"111","article-title":"[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2515\/therapie:2005005","article-title":"[Validation of a measurement scale: Example of a French Adverse Drug Reactions Preventability Scale]","volume":"60","author":"Olivier","year":"2005","journal-title":"Therapie"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2215\/CJN.12841216","article-title":"Statistical methods for recurrent event analysis in cohort studies of CKD","volume":"12","author":"Yang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.2215\/CJN.00580118","article-title":"Medication safety principles and practice in CKD","volume":"13","author":"Whittaker","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"e184852","DOI":"10.1001\/jamanetworkopen.2018.4852","article-title":"Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system","volume":"1","author":"Tonelli","year":"2018","journal-title":"JAMA Netw Open"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/ckj\/sfz046","article-title":"Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: The German chronic kidney disease study","volume":"12","author":"Schmidt","year":"2019","journal-title":"Clin Kidney J"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/ki.2015.246","article-title":"Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates","volume":"88","author":"Schneider","year":"2015","journal-title":"Kidney Int"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ekir.2019.07.014","article-title":"Achievement of low-density lipoprotein cholesterol targets in CKD","volume":"4","author":"Massy","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/jgs.13153","article-title":"Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review","volume":"62","author":"Fried","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/aje\/kwm070","article-title":"Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect","volume":"166","author":"Brookhart","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11588280-000000000-00000","article-title":"Association between glomerular filtration rate and adverse drug reactions in elderly hospitalized patients: The role of the estimating equation","volume":"28","author":"Corsonello","year":"2011","journal-title":"Drugs Aging"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semnephrol.2014.02.008","article-title":"Clinical studies and chronic kidney disease: What did we learn recently?","volume":"34","author":"Liabeuf","year":"2014","journal-title":"Semin Nephrol"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.2014121241","article-title":"The aryl Hydrocarbon receptor is a critical regulator of tissue factor stability and an antithrombotic target in uremia","volume":"27","author":"Shivanna","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: A systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/clpt.1983.192","article-title":"Reasons for disagreement in the standardized assessment of suspected adverse drug reactions","volume":"34","author":"Hutchinson","year":"1983","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.01030120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:11Z","timestamp":1786369331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.01030120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01030120","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}